+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anti Tumour Necrosis Factor"

Tumor Necrosis Factor Alpha (TNF-a) Agonist - Pipeline Insight, 2020 - Product Thumbnail Image

Tumor Necrosis Factor Alpha (TNF-a) Agonist - Pipeline Insight, 2020

  • Drug Pipelines
  • July 2020
  • 60 Pages
From
Glucocorticoid induced tumor necrosis factor - Pipeline Insight, 2020 - Product Thumbnail Image

Glucocorticoid induced tumor necrosis factor - Pipeline Insight, 2020

  • Drug Pipelines
  • July 2020
  • 60 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H1 2020 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 51 Pages
From
TNF Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025) - Product Thumbnail Image

TNF Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)

  • Report
  • January 2020
  • 115 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 10A - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 51 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 81 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

  • Drug Pipelines
  • August 2019
  • 64 Pages
From
TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions - Global Forecast up to 2025 - Product Thumbnail Image

TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions - Global Forecast up to 2025

  • Report
  • August 2019
  • 140 Pages
From
Global Psoriasis Treatment Market: By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region – North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025 - Product Thumbnail Image

Global Psoriasis Treatment Market: By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region – North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025

  • Report
  • August 2019
  • 80 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

  • Drug Pipelines
  • April 2019
  • 85 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 62 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 61 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 97 Pages
From
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry - Product Thumbnail Image

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

  • Report
  • January 2019
  • 180 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 39 Pages
From
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018

  • Drug Pipelines
  • October 2018
  • 109 Pages
From
Global TNF Inhibitors Market 2019-2023 - Product Thumbnail Image

Global TNF Inhibitors Market 2019-2023

  • Report
  • October 2018
  • 122 Pages
From
Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022 - Product Thumbnail Image

Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022

  • Report
  • September 2018
  • 115 Pages
From
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018 - Product Thumbnail Image

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

  • Drug Pipelines
  • September 2018
  • 60 Pages
From
TNF Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026 - Product Thumbnail Image

TNF Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • Report
  • August 2018
  • 198 Pages
From
Loading Indicator
adroll